BioInvent: BI-1808 meets bar in CTCL; BI-1206 in NHL slightly below threshold
Yesterday afternoon, the company released new data from two programs: BI-1808 in CTCL and BI-1206 (triple combo with AZ's Calquence) in NHL. For BI-1808 in CTCL, the dataset now includes 8 patients (up from 4 previously), showing 1 new complete response (CR), 3 partial responses (PR), and 4 stable
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.